A jury of experts from science and industry will select the best ideas with the most promising teams from all the project proposals submitted.

The project proposals for GO-Bio next funding go through a two-stage process.

A panel of experts with representatives from the international biotechnology and finance scene assesses the project applications for both phases of GO-Bio next. After a pre-selection, prioritised teams can present their projects to the jury. As a result of this jury meeting, the BMBF receives proposals for funding projects in GO-Bio next. The final funding decision is reserved for the BMBF as the funding body.

Evaluation criteria for the selection of project ideas:

• Innovation level of the project
• Economic exploitation potential and spin-off prospects
• Qualification, suitability and composition of the project team
• Quality of the R&D concept and the description of the work, time and milestone plan
• Plausibility of the financing plan

Members of the expert panel:

• Silke Beaucamp, BEAUCAMP Unternehmensberatung
• Stefan B. Beerhalter, Start2 Group GmbH / German Accelerator Life Sciences
• Dr. Annegret de Baey-Diepolder, Seventure Partners
• Dr. Juergen Gamer, TET Systems GmbH und Co. KG
• Dr. Thomas Hanke, Evotec Internationa GmbH
• Dr. Peter Heinrich, Sinfonie Life Science Management GmbH
• Dr. Regina Hodits, Wellington Partners
• Dr. Thomas Höger, Apogenix GmbH
• Marco Janezic, Blue Ribbon Partners GmbH
• Dr. Svenja Jarchow-Pongratz, Center for Entrepreneurial and Financial Studies, Technische Universität München
• Dr. Sebastian Kreuz, Boehringer Ingelheim Venture Fund GmbH
• Ulrich Mahr, Max-Planck-Innovation GmbH
• Ute Mercker, IBB Ventures
• Dr. Marianne Mertens, Apollo Health Ventures
• Dr. Achim Plum, Independent consultant
• Dr. Harald Poth, Independent Life Science Investment Consultant
• Dr. Christian Regenbrecht, CELLphenomics GmbH
• Prof. Dr. Christoph Rußmann, Health Campus Göttingen, University of Applied Sciences and Arts, Faculty of Engineering and Health
• Dr. Rupert Sandbrink, SDDCCS: Solutions for Drug Development - Consulting and Clinical Services
• Prof. Dr. med. Alexander Schachtrupp, Independent Consultant
• Dr. Isabel N. Schellinger, Angiolutions GmbH
• Dr. Andreas Schmidt, Springboard Health Angels GmbH
• Dr. Heinz Schwer, VERAXA Biotech GmbH
• Dr. Michael Thiel, Sanemus AG
• Dr. Fei Tian MIG, Capital AG
• Dr. Karen Uhlmann, OMEICOS Therapeutics GmbH
• Dr. Johannes Velling, Ministry of Economic Affairs, Industry, Climate Protection and Energy of the State of North Rhine-Westphalia
• Dr. Angelika Vlachou, High-Tech Gründerfonds
• Dr. Jens Wiehler, BioM Biotech Cluster Development GmbH
• Dr. Johannes B. Wöhrstein, mbiomics GmbH